Current meningococcal vaccines and bacterial carriage


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The review presents information on the immunological and epidemiological efficacy of current meningococcal conjugate polysaccharide and protein (against serogroup B) vaccines. All literature sources indicate not only the high epidemiological efficacy of conjugate polysaccharide vaccines, but also their undoubted effects on the prevalence of carriage of the meningococcal serogroup homologous to the vaccine. Lower carriage is detected no earlier than several months after mass immunization. The protein vaccines against meningococcal serogroup B disease have high immunogenicity and epidemiological efficacy only if the composition of the vaccine is consistent with the protein antigens of the strain that causes the disease, mostly against porin A. In the insignificant number of studies so far, the direct effect of this vaccine on the prevalence of meningococcal serogroup B carriage could not be noted, but the groups are found to have a lower carriage of all meningococcal strains several months after immunization, which is explained by the cross-reactive antigens in the vaccine. Whether meningococcal carriage is completely eradicated under current conditions is discussed.

全文:

受限制的访问

作者简介

N. Kostyukova

Honored Academician N.F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of Russia

Email: nathakos@mail.ru
MD, Honored Scientist of the Russian Federation, Leading Researcher Moscow, Russia

V. Bekhalo

Honored Academician N.F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of Russia

Email: bekhalo@gamaleya.org
Cand. Biol. Sci., Leading Researcher Moscow, Russia

参考

  1. Gotschlich E.C., Liu T.U., Artenstein M.S. Human immunity to meningococcus. III. Preparation and immunological properties of the group A, group B and group C meningococcal polysaccharides. J. Exp. Med. 1969; 129: 1349-65.
  2. Goldschneider J., Gotschlich E.C., Artenstein M.S. Human immunity to meningococci. I. The role of humoral antibodies. J. Exp. Med. 1969; 129: 1307-26.
  3. Artenstein M.S., Gold R., Zimmerly J.G., Schneider Y., Harkins Ch. Prevention of meningococcal disease by group C polysaccharide. N. Engl. J. Med. 1969; 272: 417-20.
  4. Костюкова Н.Н., Бехало В.А. Современные менингококковые вакцины: сильные и слабые стороны, ближайшие перспективы. Эпидемиология и вакцинопрофилактика 2016; (4): 64-73.
  5. Платонов А.Е., Харит С.М., Платонова О.В. Вакцинопрофилактика менингококковой инфекции в России и в мире. Эпидемиология и вакцинопрофилактика 2009; (5): 32-46.
  6. Костюкова Н.Н., Бахаев Ю.П., Беломестных Е.Л., Дуплищева В.А., Кирпичникова Е.Н., Кузмин Ю.К., Ламажаа А.М., Луночкина М.А., Мазуренко М.К., Оюн Д.Н. и др. Опыт массовой вакцинопрофилактики менингококковой инфекции среди детей. В кн.: Острые менингиты. Сборник научных трудов. М.: НИИЭМ им. Н.Ф. Гамалеи, 1982; 31-7.
  7. Чернышева Т.Ф., Скирда Т.А., Чистякова В.Г., Королева И.С. Вакцинопрофилактика менингококковой инфекции. Эпидемиология и вакцинопрофилактика 2003; (3): 44-6.
  8. Колесников А.В., Козырь А.В., Шемякин И.Г., Дятлов И.А. Современные представления о механизме активации иммунного ответа конъюгированными полисахаридными вакцинами. Журн. микробиол. 2015; (3): 97-106.
  9. World Health Organization. Meningococcal meningitis. Emergency preparations and response. 2018. http/www.who. int/csr/disease/meningococcal/en
  10. Trotter C.L., Maiden Мии. Meningococcal vaccine and herd immunity: lessons, learned from serogroup conjugate vaccination programmes. Expert. Rev. Vaccines 2009; 8(7): 851-61.
  11. Ishola D.A., Borrow R., Findlow H., Findlow J., Trotter C.L., Ramsay M. Prevalent of serum bactericidal antibodies to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin. Vaccine. Immunol. 2012; 19(8): 1126-30.
  12. Borrow R. Advances with vaccination against Neisseria meningitidis. Trop. Med. Intern. Health 2012; 17(12): 1478-91.
  13. Borrow R, Alarcon P., Carlos J., Caugant D., Christensen H., Deblag R. et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev. Vaccines 2017; 16(4): 313-28.
  14. Maurice J. Vaccine storage threatens spread of meningococcus in Niger. Lancet 2015; 385: 2241.
  15. Daugla D.M., Garni J.P., Gamougam K., Naibei N., Mbainnadji L., Narbe M. et al. Effect of serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. Lancet 2014; 383: 40-7.
  16. Novak R.T., Kambou J.L., Diomande F.V., Tarbangdo T.F., Quedrado-Fraore K., Sangare et al. Segroup A meningococcal conjugate vaccination in Burkina-Faso: analysis of national surveillance data. Lancet Infect. Dis. 2012; (12): 354-63.
  17. Collard J.M., Issaka B., Zaneidou M., Higonnet S., Nicolas P. Taha M.-Kh. Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination. BMC Infect. Dis. 2013; 13: 576.
  18. Kristiansen P.A., KuBa A., Quedraogo F.-S., Salam J., Quedraogo R., Sangare L., Diomande F. et al. Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac. BMC Infect. Dis. 2014; 14: 663.
  19. Stuart J.M. Impact of serogroup A meningococcal conjugate vaccine in Africa. Human Vaccines & Immunutherapeutics 2018. https://doi.org/10.1080/216455.2017.1412022
  20. Королева М.А., Миронов К.О., Королева И.С. Эпидемиологические особенности генерализованных форм менингококковой инфекции, обусловленной Neisseria meningitidis серогруппы W, в мире и в Российской Федерации. Эпидемиол. инфекц. болезни. Актуал. вопр. 2018; (3): 16-23.
  21. Frota A.C.C., Millagres L.G., Harrison L.M, Ferreira B., Barroto D.M., Pereira G.S. et al. Immunogenisity and safety of meningococcal conjugate vaccine in schoolchildren and teenagers infected and uninfected with HIV in Rio-de-Janeiro, Brasilia. Pediatr. Infect. Dis. J. 2015; 34(51): E113-8.
  22. Костинов М.П., Тарасова А.А. Вакцинация детей с гемо-бластозами. Эпидемиология и вакцинопрофилактика 2017; (1): 76-7.
  23. Fierbig T., Bertri F., Freiberger F., Pinto V., Claus H., Romano M.R. et al. Functional expression of the capsule polymerase of Neisseria meningitidis serogroup X: a new perspective for vaccine development. Glycobiology 2014; 24(2): 150-8.
  24. Tonneato D., Pizza M., Mazignani V., Rappuoli R. Emerging experience with meningicoccal serogroup B protein vaccines. Expert. Rev. Vaccines 2017; 16(5): 433-51.
  25. Tan L.K.K., Carlone G.M., Borrow R. Advances in the development vaccines against Neisseria meningitidis. N. Engl. J. Med. 2010; 362(16): 1511-20.
  26. Nadel S. Prospects for eradication of meningococcal disease. Arch. Dis. Child. 2012; 97: 993-8.
  27. Pizza M., Scarlato V., Masignani V., Frico B., Comanucci M., Jenings G.F. et al. Identification of vaccine candidate against serogroup B meningococcus by whole-genome sequesing. Science 2009; 287(5459): 1816-20.
  28. McIntosh E.X., Carey V., Tonneato D., Dull P., James W. Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals - the example of serogroup B meningococcal infection. Ther. Adv. Vaccines 2015; 3(1): 13-23.
  29. Романова Ю.М., Гинцбург А.Л. Бактериальные биопленки как естественная форма существования бактерий в окружающей среде и организме хозяина. Журн. микробиол. 2011; (3): 99-109.
  30. Caugan D.A., Hoiby E.A., Magnus P., Schneel O., Hoel F., Bjuna G. et al. Asymptomatic carriage of Neisseria meningitidis in randomly sampled population. J. Clin. Microbiol. 1994; 32(2): 323-30.
  31. Stephens D. Uncloaking the meningococcus: dynamics of carriage and disease. Lancet 1999; 353: 941-2.
  32. Harrison L.H., Shutt K.A., Arnold K.E., Stern E.I., Pondo T. Meningococcal carriage among Georgia and Maryland High school students. J. Infect. Dis. 2015; 2011(11): 1761-8.
  33. Christensen H., May M., Bowen J., Hickman M., Trotter C.L. Meningococcal carriage by age: a systematic review. Lancet Infect. Dis. 2010; 10(12): 853-61.
  34. Caugant D.A., Maiden M.C.J. Meningococcal carriage and disease - population biology and evolution. Vaccine 2009; 27(4): B64-B70.
  35. Миронов К.О., Тагаченкова Т.А., Королева И.С., Платонов А.Е., Шипулин Г.А. Генетическая характеристика штаммов Neisseria meningitidis, выделенных от здоровых носителей в очагах менингококковой инфекции. Журн. микробиол. 2011; (2): 22-7.
  36. Jarvis G.A. Recognition and control of neisserial infections by antibody and complement. Trends Microbiol. 1995; 33: 198-201.
  37. Yoshwich K.O., McCaw S.E., Strobel L., Fros A. M., Gray-Owen S.W. Sterilizing immunity elicited by Neisseria meningitidis carriage shows broader protection than predicted by serum antibody-cross reactivity in CEACAM-humanized mice. Infect. Immun. 2015; 83(2): 354-63.
  38. Горлина М.Х., Костюкова Н.Н., Мильдзихова И.Б., Чернышева Т.Ф., Мишина А.И., Скирда Т.А., Kayhthy H. Серотипы и субтипы Neisseria meningitidis, циркулирующие среди бактерионосителей в Москве (1989-1991). Журн. микробиол. 1994; приложение: 44-8.
  39. Jones J.Z., Christodoulides M., Brooks J.L., Miller A.R.O., Cartwright K.A.V., Heckels J.E. Dynamics of carriage in a group of military recruits: subtype stability and specifity of immune response, following colonization. J. Infect. Dis. 1998; 178: 451-9.
  40. Horton R.E., Stuart H., Christensen H., Borrow R., Guthrie T., Davenport V. et al. Influence of age and carriage status on salivary IgA to Neisseria meningitidis. Epidemiol. Infect. 2005; 133: 882-9.
  41. Davenport V., Guthrie T., Findlow J., Borrow P., Williams N.A., Heyderman R.S. Evidence for naturally acquired T cell-mediated immunity to Neisseria meningitidis by Neisseria meningitidis. J. Immunol. 2003; 171: 4263-70.
  42. Nurkka A., MacLennan J., Jantir V., Obaro S., Greenwood B., Kayhthy Y. Salivary antibody response to vaccination with meningococcal A/C polysaccharide vaccine in previously vaccinated and unvaccinated Gambian children. Vaccine 2001; 19(4-5): 547-57.
  43. Zang Q., Finn A. Mucosal immunology against pathogenic nasopharyngeal bacteria. J. Clin. Pathol. 2004; 57(10): 1015-25.
  44. Read R.C., Baxter D., Hadwick D.R., Faust S.N., FinnA., Gordon St.-B. et al. Effect of quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine on meningococcal carriage: a observer blind phase randomized clinical trail. Lancet 2014; 384: 2123-31.
  45. Фаворова Л.А., Телешевскпя Э.Я. Эпидемиология и профилактика менингококковой инфекции. Советская медицина 1971; (1): 113-8.
  46. Breakwell L., Whaley M., Khan U.I., Bandy U., Alexander-Scott N., Dupont L. et al. Meningococcal carriage among university student population - United States, 2015. Vaccine 2018; 36: 29-35.
  47. Soeters H.M., Whaley M., Scott N.A., Kanadaniau K.V., MacNeil J.K. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a College-Rhode Island, 2015-2016. Clin. Infect. Dis. 2017; 64(8): 1115-22.
  48. McNamara L.A., Thomas J.D., MacNeil D., Chang H.Y., Day M., Fisher E., et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak -Oregon, 2015-2016. J. Infect. Dis. 2017; 216: 1130-40.
  49. Balmer P.,Burmen C., SierraL., York L.J. Impact ofmeningococcal vaccination on carriage and disease transmission: A review of the literature. Human Vaccine & Immunotherapeuetics 2018; (5): 1118-30.
  50. Maiden M.C.J., Frosch M. Can we, should we eradicate the meningococcus? Vaccine 2012; 30(6): 652-6.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2019
##common.cookie##